The APAC Pyrogen Testing Market size was worth USD 148.56 million in 2022 and is estimated to grow at a CAGR of 16.7% to reach USD 321.55 million by 2027.
The pyrogen test plays a vital role in advanced medical care, which works for presenting the presence of pyrogens in an organism and medical devices responsible for causing fever, also found in lipopolysaccharides and lipoteichoic acid. These contaminated pyrogens pose harmful effects such as fever in the human body, which can be transferred through injections contaminated after administration, causing temperature dysregulation, swelling, multiple organ failure, and other life-threatening conditions at critical conditions.
Increasing investments in the manufacturing of these products by governments of various countries for the safe introduction of infection-free products to market is accelerating the rise of the pyrogen testing market in the Asia-Pacific region. In addition, increasing awareness for more diagnoses among parents, the development of lifesaving devices for children, and increased demand for pyrogen testing products are contributing to the market's growth rate. Rising awareness of pyrogen testing among people is boosting the market growth in this region. The people’s awareness of the importance of pyrogen testing regulatory authorities sparked the development of more innovative and technologically advanced products on the market that are quicker, more accurate, and more reasonably priced than traditional methods and devices.
In addition, the growing number of biologic products and emphasis on R&D by the key market participants, rise in response to fast-developing pharmaceutical and biotechnology manufacturing, and an increasing number of new therapy promotions are majorly fuelling the pyrogen testing market growth in the APAC region. Furthermore, increasing manufacturing companies and government investments to conduct R&D for new product development propel market growth. In addition, the key players in the region are implementing various strategies to gain a competitive advantage over the marketplace. On the other hand, the pyrogen testing market is predicted to increase significantly with many biological products.
Furthermore, growing government assistance and the introduction of new medications are also boosting the pyrogen testing market growth. This has also contributed to the large-scale development of therapeutically improved pharmaceuticals, forcing producers to improve productivity, cost efficiency, and variations. As a result, companies are implementing good manufacturing practices through biological testing at various stages of the production cycle, adding to the market’s growth.
However, the market's growth is expected to be hampered by strict regulatory policies, ambiguous reimbursement concerns, and a lack of understanding regarding modern testing processes. Distribution, marketing, and manufacturing control through stringent government regulations, which are challenging for market players to sell medical devices, are the major factors anticipated to restrain the growth of the pyrogen testing market in APAC during the forecast period. In addition, large regional companies can only afford the high capital investment in these testing devices and their costly manufacturing, leaving the developing countries and middle and low-income economies behind. This is foreseen to obstruct the market growth of pyrogen testing across the region of APAC.
This research report on the Asia-Pacific pyrogen testing market has been segmented and sub-segmented into the following categories:
By Test Type:
Geographically, the Asia Pacific is expected to be the fastest developing regional market globally, owing to the constantly growing population and rising healthcare expenditure. Many pharmaceutical companies concentrate on Asian countries like China and India for drug development, growth, and production. Clinical research organizations in the Asia Pacific are now contributing to clinical trials. The availability of less stringent government rules for drug production, a giant gene pool, and a fast-increasing healthcare infrastructure are primary elements driving the sector’s expansion in this field. Clinical trial groups are concentrating their efforts in Asian countries. The countries such as China, India, South Korea, Japan, Australia, and the rest of Asia Pacific are expanding the APAC Asian pyrogen testing market.
Due to its large population, the Chinese pyrogen testing market is expected to account for a substantial share of the APAC market during the forecast period. In addition, there are around 800 novel compounds in the pipeline among the local biotech firms based in China, with 70-80 in phase III. Therefore, among the major countries contributing to the high revenue share in the regional market for pyrogen testing, China is anticipated to show the highest growth rate in the region. This dominance of the country is owing to factors such as the high prevalence of chronic and infectious diseases, high frequency of rapid technological advancements, improved regulatory framework, presence of significant pyrogen testing players, strong presence of pharmaceutical companies, and less stringent government regulation in drug development. Additionally, the presence of well-developed healthcare infrastructure is one factor that is further anticipated to rad to the growth of the pyrogen testing market in China, resulting in the overall driving of the market for pyrogen testing in the APAC region.
The Indian pyrogen testing market is one of the fastest-growing countries in the region. The market growth is supported by rising disposable income, improving the healthcare sector, and favorable reimbursement policies. In addition, India has been taking substantial steps to promote itself as the world’s leading central biopharmaceutical innovation hub, including fostering Public-Private Partnerships (PPPs) in biopharmaceutical research and development projects.
The Japan pyrogen testing market is anticipated to grow at a healthy CAGR during the forecast period. Owing to rapid urbanization, developed healthcare infrastructure, high laboratory automation across various medical settings, strict regulations, and the presence of major pharmaceutical and biotechnology companies, the pyrogen testing market in Japan is expected to grow significantly during the forecast period. Furthermore, the development of technologically advanced pyrogen testing devices with improved efficiency to provide better patient outcomes, along with collaboration with other foreign market players to increase their profits for R&D activities, are additional strategies that several leading players are gradually putting into practice to maintain competition in the market. This has led to the expansion of the Japanese pyrogen testing market.
The South Korean pyrogen testing market is likewise working to establish itself as a worldwide biotech center, focusing on biosimilars, vaccine development, and stem cell therapies. In addition, the growing need for rehabilitative treatments for life-threatening diseases like cancer and diabetes underscores the necessity for medication research and development and, thus, the demand for pyrogen testing kits for effective quality testing and management.
KEY MARKET PLAYERS:
Companies playing a promising role in the APAC pyrogen testing market profiled in this report are Associates of Cape Cod, Inc., Lonza Group, Merck KGaa, Thermo Fisher Scientific, Ellab A/S, Genscript, Hyglos GmbH, Charles River Laboratories, Inc., Wako Chemicals USA, Inc., and WUXI Pharmatech (Cayman) Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com